Diabetes

The AJMC® Diabetes compendium is a comprehensive resource for clinical news and expert insights for the chronic condition.

Latest News

Gestational diabetes | Image credit: Phushutter - stock.adobe.com
Questionnaire Evaluates Obstetric Nurse Competency in Managing Gestational Diabetes

May 8th 2025

A validated questionnaire assesses skills, knowledge, and attitudes for effective gestational diabetes management.

Diabetes monitoring | Image credit: abidika - stock.adobe.com
New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

April 23rd 2025

Rural health sign | Image credit: BJP7images - stock.adobe.com
FQHCs Show Low Engagement in Hypertension, Diabetes Trials

April 15th 2025

AI representation of housing stability | Image credit: GoldPumaze - stock.adobe.com
Housing Instability Linked to Worse Type 2 Diabetes Outcomes

April 14th 2025

Diabetes concept | Image credit: Sherry Young - stock.adobe.com
GLP-1 RAs, SGLT2 Inhibitors Associated With Reduced MACE, HHF in Patients With Diabetes

April 9th 2025

More News

Mendelian Randomization Study Shows Vitamin D Deficiency Not Associated With T1D
February 25th 2021

Mendelian Randomization Study Shows Vitamin D Deficiency Not Associated With T1D

Gianna Melillo
Genetically decreased vitamin D levels are unlikely to have a large effect on risk of type 1 diabetes, according to results of a Mendelian randomization study published in PLOS Medicine.
How Does Maternal Diet Impact Childhood Weight?
February 22nd 2021

How Does Maternal Diet Impact Childhood Weight?

Gianna Melillo
Low-quality maternal diets may increase the odds of offspring being considered overweight or obese, according to study results published in BMC Medicine.
Phase 3 Trials Show Lilly’s Tirzepatide Reduces A1C, Body Weight Among Patients With T2D
February 18th 2021

Phase 3 Trials Show Lilly’s Tirzepatide Reduces A1C, Body Weight Among Patients With T2D

Gianna Melillo
The SURPASS program, which consists in part of SURPASS-3 and SURPASS-5, is testing the efficacy and safety of tirzepatide, a novel investigational once-weekly dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Trial Finds Semaglutide With Lifestyle Intervention Reduces Body Weight by Nearly 15%
February 10th 2021

Trial Finds Semaglutide With Lifestyle Intervention Reduces Body Weight by Nearly 15%

Gianna Melillo
In the placebo-controlled trial, 86% of participants who received semaglutide attained at least a 5% reduction in total body weight.
Prediabetes May Not Necessitate Diabetes Development in Older Adults
February 8th 2021

Prediabetes May Not Necessitate Diabetes Development in Older Adults

Gianna Melillo
Prediabetes may not be a robust diagnostic biomarker for predicting future diabetes development in older adults.
GD May Increase Heart Disease Risk Despite Achieving Normal Blood Glucose Levels
February 3rd 2021

GD May Increase Heart Disease Risk Despite Achieving Normal Blood Glucose Levels

Gianna Melillo
Results of a prospective cohort study suggest history of gestational diabetes (GD) may promote development of atherosclerotic plaque, potentially increasing the risk of future heart disease among women, even in the absence of hyperglycemia.
Recognizing the Role of Systemic Racism in Diabetes Disparities
February 2nd 2021

Recognizing the Role of Systemic Racism in Diabetes Disparities

Gianna Melillo
There needs to be broad acceptance of the role systemic racism plays in social determinants of health in order to improve metabolic outcomes among minority populations in the United States.
Heart
January 27th 2021

Insulin Resistance, Diabetes Strongly Linked With Premature CHD Among Women

Gianna Melillo
A prospective cohort study found that diabetes and insulin resistance were the strongest risk factors for premature onset of coronary heart disease (CHD) among American women. Results were published in JAMA Cardiology.
Metabolic Surgery Superior to Drug Therapy at Controlling Type 2 Diabetes, Study Says
January 25th 2021

Metabolic Surgery Superior to Drug Therapy at Controlling Type 2 Diabetes, Study Says

Gianna Melillo
Metabolic surgery is more effective than conventional medical therapy in the long-term control of type 2 diabetes (T2D), according to results of a 10-year follow-up study of a randomized controlled trial published in The Lancet.
Study Weighs Perceived Benefits, Costs of RDM Adoption for Diabetes Management
January 20th 2021

Study Weighs Perceived Benefits, Costs of RDM Adoption for Diabetes Management

Gianna Melillo
Results of a vignette-based survey study indicate patients with diabetes require greater health benefits to adopt more intrusive remote digital monitoring (RDM), food monitoring, and real-time feedback by a health care professional.
Trial Finds Bimagrumab Aids Weight Loss in Patients With T2D, Obesity
January 18th 2021

Trial Finds Bimagrumab Aids Weight Loss in Patients With T2D, Obesity

Gianna Melillo
Results of a phase 2 trial showed that an activin type II receptor blockade, achieved via bimagrumab, led to significant loss of fat mass, gain in lean mass, and metabolic improvements among patients with type 2 diabetes (T2D) and overweight or obesity.
Diabetes definition page
January 13th 2021

Black Americans With T1D, COVID-19 Have Increased Risk of Hospitalization for DKA

Gianna Melillo
Non-Hispanic Black individuals with type 1 diabetes and coronavirus disease 2019 infections may be more likely to be hospitalized for diabetic ketoacidosis (DKA) compared with non-Hispanic White patients.
ADA Survey Highlights COVID-19’s Impact on Americans With Diabetes
January 11th 2021

ADA Survey Highlights COVID-19’s Impact on Americans With Diabetes

Gianna Melillo
A new American Diabetes Association (ADA) survey highlights how the coronavirus disease 2019 (COVID-19) pandemic took a toll on the population with diabetes, which is one of the most prevalent preexisting conditions in America.
FDA logo
January 11th 2021

Jardiance 1 Step Closer to FDA Approval for Use in Heart Failure

Maggie L. Shaw
The FDA today accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for Jardiance (empagliflozin), the sodium glucose co-transporter 2 inhibitor being investigated for use in patients with heart failure.
Michael Snyder, PhD
January 7th 2021

Michael Snyder Discusses How Precision Health Measurements Can Impact Diabetes Detection and Management

Michael Snyder, PhD, professor and chair of genetics at the Stanford University School of Medicine, discusses the ways in which precision health measurements can aid physicians in detecting and better managing diabetes.
Improved Periconception A1C Linked to Reduction in Adverse Pregnancy Outcomes
January 4th 2021

Improved Periconception A1C Linked to Reduction in Adverse Pregnancy Outcomes

Gianna Melillo
A reduction in glycated hemoglobin (A1C) may result in improved perinatal and maternal outcomes among women with prepregnancy diabetes, according to results of a cohort study published in JAMA Network Open.
Machine Learning Predicts Incidence of Gestational Diabetes
December 30th 2020

Machine Learning Predicts Incidence of Gestational Diabetes

Gianna Melillo
Using advanced machine learning models, researchers in China were able to accurately predict incidence of gestational diabetes among pregnant women during their first trimester.
Top 5 Most-Read Diabetes Articles of 2020
December 23rd 2020

Top 5 Most-Read Diabetes Articles of 2020

Gianna Melillo
Advancements in coverage for diabetes technology and improvement in diabetic retinopathy screening rates appear on this year’s list of most-read diabetes articles.
Review Details Relationship Between Frailty, Diabetes in Older Populations
December 22nd 2020

Review Details Relationship Between Frailty, Diabetes in Older Populations

Gianna Melillo
The identification and assessment of frailty, defined as a state of increased vulnerability to adverse health outcomes resulting from loss of physiological reserve, should become a routine aspect of diabetes care, authors of a systematic review and meta-analysis published in The Lancet Health Longevity argued.
Empagliflozin Linked to 20% Drop in Care Costs for T2D, CVD
December 15th 2020

Empagliflozin Linked to 20% Drop in Care Costs for T2D, CVD

Gianna Melillo
An outcomes-based agreement conducted by Boehringer Ingelheim and Highmark found that use of Jardiance (empagliflozin) among adults with type 2 diabetes (T2D) and known cardiovascular disease (CVD) was associated with a total cost of care savings of over 20%.
Poxel's PXL770 Shows Promise in Patients With NASH, T2D
December 14th 2020

Poxel's PXL770 Shows Promise in Patients With NASH, T2D

Gianna Melillo
Results from a phase 2 trial show PXL770 yielded consistently greater responses in high-risk patients with comorbid nonalcoholic steatohepatitis (NASH) and type 2 diabetes (T2D) compared with placebo.
Experts Discuss Benefits, Limitations of Pediatric Obesity Interventions
December 7th 2020

Experts Discuss Benefits, Limitations of Pediatric Obesity Interventions

Gianna Melillo
During a session at the at the 18th annual World Congress Insulin Resistance, Diabetes & Cardiovascular Disease presented by the Metabolic Institute of America, experts outlined the benefits and limitations of pharmacological, surgical, and lifestyle interventions for pediatric patients with obesity.
Dr Paul Zimmet Outlines COVID-19, Diabetes Challenges and Lessons Learned From the Pandemic
December 4th 2020

Dr Paul Zimmet Outlines COVID-19, Diabetes Challenges and Lessons Learned From the Pandemic

Gianna Melillo
In a session at the 18th annual World Congress Insulin Resistance, Diabetes & Cardiovascular Disease presented by the Metabolic Institute of America, experts discussed challenges faced by patients with diabetes in the wake of the coronavirus disease 2019 (COVID-19) pandemic and lessons learned from the crisis.
Kentucky Telemedicine Program Increases Diabetic Retinopathy Screening Rates
November 28th 2020

Kentucky Telemedicine Program Increases Diabetic Retinopathy Screening Rates

Gianna Melillo
Large telemedicine diabetic retinopathy screening networks based in federally designated safety-net clinics may be able to increase screening access and compliance among otherwise underscreened populations.
Scale wrapped with measuring tape
November 18th 2020

NDPS Data Show Minor Weight Loss Can Almost Halve T2D Risk

Gianna Melillo
For individuals currently in high-risk glycemic categories, losing 2 to 3 kg (4.5-6.5 lb) in combination with increased physical activity over 2 years nearly halved the risk of developing type 2 diabetes (T2D).
Individual hold heart
November 16th 2020

Most Patients With T2D Classified as "High Risk" for Fatal Heart Attack, Stroke

Gianna Melillo
Half of patients with type 2 diabetes (T2D) exhibit very high cardiovascular risk while the majority are at a high risk of fatal heart attack or stroke, according to new research published in the European Journal of Preventive Cardiology.
Paper cutouts of people of various colors
November 14th 2020

Reducing Racial, Ethnic Disparities in Diabetes Prevalence Requires a Multifaceted Approach

Skylar Jeremias
Lowering the higher rates of diabetes seen among racial and ethnic minorities requires solutions to address all of the major factors that contribute to diabetes prevalence.
Race Impacts DME Treatment Efficacy, Study Finds
November 10th 2020

Race Impacts DME Treatment Efficacy, Study Finds

Gianna Melillo
Black individuals with diabetic macular edema (DME) exhibited a significantly lower likelihood of visual acuity improvement following intravitreal bevacizumab treatment compared with White and Hispanic patients.
Two-Year Data Show Combined Efficacy of GLP-1 RAs, SGLT2s for T2D
November 6th 2020

Two-Year Data Show Combined Efficacy of GLP-1 RAs, SGLT2s for T2D

Gianna Melillo
New data show combining glucagon-like peptide-1 receptor agonist (GLP-1 RA) exenatide plus sodium–glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin remains effective after 2 years for type 2 diabetes (T2D) uncontrolled with metformin.
What We’re Reading: J&J Loses Appeal; Opioid Settlement in the Works; Diabetes Prevention Results Released
November 4th 2020

What We’re Reading: J&J Loses Appeal; Opioid Settlement in the Works; Diabetes Prevention Results Released

AJMC Staff
A decision was upheld that Johnson & Johnson (J&J) must pay a $2.1-billion fine from a 2018 court decision; 3 major drug distributors face up to $18 billion in opioid-related fines; a new diabetes prevention platform may assist in symptom prevention.
<1
...
91011121314151617
...
98>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo